ANTHRAX

Thravixa™
(Fully Human Anthrax Monoclonal Antibody)
Vaccine Candidate

Thravixa™ (Fully Human Anthrax Monoclonal Antibody) is being studied for use against symptomatic anthrax infection. This candidate is derived from an individual immunized with BioThrax^® (Anthrax Vaccine Adsorbed).
 

Active Clinical Trials  LEARN MORE

ANNOUNCEMENTS
Emergent BioSolutions Receives Orphan Drug Designation for Its Investigational Monoclonal Antibody for the Treatment of Inhalation Anthrax

Emergent BioSolutions Receives Fast Track Designation for Its Investigational Monoclonal Antibody for the Treatment of Inhalational Anthrax

Emergent BioSolutions Announces Commencement of Phase I Clinical Trial for Monoclonal Antibody to Treat Inhalational Anthrax

Top of Page